Navigation Links
Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
Date:5/3/2012

nclude Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics. 

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Without a known ligand, drug development for a given receptor is extremely difficult.

Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patie
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , Mexique, July 3, 2015 ... cible les épidémies que sont l,hypertension, le diabète ... l,intermédiaire de plateformes éducatives gratuites et d,une conférence ... (Photo: http://photos.prnewswire.com/prnh/20150630/227033 ) , ... en ligne , Prendre en charge l,hypertension ...
(Date:7/3/2015)... NEW YORK , July 3, 2015  Obsidian ... ) - an online service for the management of ... professionals announced today that PharmaShine now includes the 2014 ... Center for Medicare Services on June 30. The data ... 11.4 million transactions between industry and providers totaling $6.49 ...
(Date:7/2/2015)... Chine, 3 juillet 2015 BGI a annoncé ... débit de l,ADN situé à Hong ... l,American College of Pathologists  (Collège des pathologistes américains, ... Hong Kong constituent le premier ... recevoir la certification du CAP en Chine, car ...
Breaking Medicine Technology:Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2
... Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced ... accepted for review by the regulatory agencies of the ... France and Spain .  OraVerse is the ... return of normal sensation and function following routine dental procedures. ...
... July 13 /Havel,s Incorporated/ - Havel,s Incorporated, ... the release of a new line of needles with Micro ... the new MLE™ echogenic feature because it does not affect ... wires or catheters through the cannula without obstruction," says ...
Cached Medicine Technology:Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 2Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 3Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 4Havel's Incorporated Announces the Release of Four New Innovative Ultrasound Needles 2
(Date:7/6/2015)... , ... July 06, 2015 , ... World renowned ... opportunity to achieve their ideal appearance through comprehensive treatment solutions. Individuals that want to ... the doctor and receive a plan that resolves each of their needs. , ...
(Date:7/6/2015)... ... July 06, 2015 , ... Promero, a leading cloud ... Software Unified IP contact center solution hosted by Promero. Randstad Technologies,a leading ... its future call center platform. , Promero will implement and manage the ...
(Date:7/6/2015)... United Kingdom (PRWEB) , ... July 06, 2015 , ... ... app could help. More than 29 million Americans have diabetes, the majority of which ... 86 million U.S. adults or more than one in three, have prediabetes (abnormally high ...
(Date:7/6/2015)... ... ... The Path of Least Resistance: The Evolution of Capitalism and Politics in ... over the past 40 years. The book explores the evolution of the global economy ... a time capsule that chronicles the economic development of the United States — from ...
(Date:7/5/2015)... Boston, MA (PRWEB) , ... July 06, 2015 , ... ... Boston Triathlon. City Sports will co-produce two training clinics for first-time triathletes this summer ... two clinics will take place on Thursday, July 9, at 6:00 p.m. at the ...
Breaking Medicine News(10 mins):Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... but not mother,s, weight and elevated enzymes , , THURSDAY, ... early-onset obesity are at increased risk for elevated liver ... , Researchers evaluated 1,732 children, average age 42, of ... of families in Framingham, Mass. The researchers found that ...
... Escalon Medical,Corp. (Nasdaq: ESMC ) today ... the State Food and Drug Administration within the,People,s ... E/Z-Scan(R) series,of products in that country. The PacScan(R) ... in both cataract and refractive,surgery. The E/Z- Scan(R) ...
... Doses Against the Most ... Types in the U.S., PHILADELPHIA, April 3, 2008 ... U.S. Food and Drug Administration,(FDA) has approved ROTARIX(R) [Rotavirus ... infants. ROTARIX will offer,protection against the most commonly circulating ...
... April 3, 2008 Facial trauma,is a too ... and Congresswoman Carolyn McCarthy (D-N.Y.) hopes to raise,awareness ... a congressional,resolution (H. Res. 1062) to designate April ... http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ), An estimated 5 million ...
... not frequency, study suggests , , THURSDAY, April 3 ... relate to each other affects the quality -- but ... twos." And a child,s temperament plays a role in ... a new study. , Interactions between 60 mothers and ...
... intake 30% decreased infection-fighting cells , , THURSDAY, April 3 (HealthDay ... it,s "starve a cold, feed a fever" or vice versa. ... study of deer mice has found that reducing the amount ... findings are published in the May/June issue of Physiological ...
Cached Medicine News:Health News:Dads' Early-Onset Obesity Linked to Liver Disease in Kids 2Health News:Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems 2Health News:Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems 3Health News:FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE 2Health News:FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE 3Health News:FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE 4Health News:FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE 5Health News:Oral and Maxillofacial Surgeons Raise Awareness About the Importance of Facial Protection 2Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:Eating Less May Hinder Immune System 2
... the result of DEKA s new ... three different methods capable of restoring ... This treatment is designed to dramatically ... the combined action of a localized ...
... Smartepil II Plus is the latest evolution ... fast, safe and reliable system for epilation ... preset protocols in its modern software, Smartepil ... vascular treatments in full respect of the ...
This instrument measures intraocular pressure without,contacting. Alignment is performed semi-automatically....
The convenience of safe and precise Patient Controlled Analgesia in a flexible system designed with advanced technology. This is progressive, innovative, and effective pain management in a sophistica...
Medicine Products: